This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moore, M D Articles by Nemerow, G R Search for Related Content PubMed PubMed Citation Articles by Moore, M D Articles by Nemerow, G R

 Previous Article  |  Next Article 

J Virol. 1991 July; 65(7): 3559-3565

Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.

Department of Immunology, Scripps Clinic and Research Foundation, La Jolla, California 92037.

ABSTRACT

The extracellular domain of CR2, the Epstein-Barr virus (EBV)/C3d receptor of B lymphocytes, contains 15 or 16 tandemly arranged short consensus repeat elements (SCR). Recombinant CR2 proteins containing SCR 1 and 2 fused to Staphylococcus aureus protein A (PA-CR2) and to murine complement factor H SCR 20 (CR2FH) were expressed in Escherichia coli and in insect cells, respectively. These recombinant CR2 molecules retained functional activity as indicated by their ability to bind to C3dg in an enzyme-linked immunosorbent assay and to inhibit EBV gp350/220 binding to B cells. PA-CR2 and CR2FH were as efficient in blocking EBV gp350/220 binding as the full-length CR2 extracellular domain, indicating that the first two SCR of CR2 contain the majority of the ligand binding activity of the receptor. PA-CR2 and CR2FH inhibited EBV-induced B-cell proliferation in vitro and blocked the development of EBV-induced lymphoproliferative disease in severe combined immunodeficient mice reconstituted with human lymphocytes. These studies indicate that soluble forms of truncated CR2 proteins may have potential therapeutic value in the treatment of EBV-induced lymphoproliferative disorders in humans that involve viral replication.

This article has been cited by other articles:

• Hutt-Fletcher, L. M. (2007). Epstein-Barr Virus Entry. J. Virol. 81: 7825-7832 [Full Text]  
• Asher, D. R., Cerny, A. M., Finberg, R. W. (2005). The erythrocyte viral trap: Transgenic expression of viral receptor on erythrocytes attenuates coxsackievirus B infection. Proc. Natl. Acad. Sci. USA 102: 12897-12902 [Abstract] [Full Text]  
• Gaggar, A., Shayakhmetov, D. M., Liszewski, M. K., Atkinson, J. P., Lieber, A. (2005). Localization of Regions in CD46 That Interact with Adenovirus. J. Virol. 79: 7503-7513 [Abstract] [Full Text]  
• Buchholz, C. J., Koller, D., Devaux, P., Mumenthaler, C., Schneider-Schaulies, J., Braun, W., Gerlier, D., Cattaneo, R. (1997). Mapping of the Primary Binding Site of Measles Virus to Its Receptor CD46. J. Biol. Chem. 272: 22072-22079 [Abstract] [Full Text]  
• Iwata, K., Seya, T., Yanagi, Y., Pesando, J. M., Johnson, P. M., Okabe, M., Ueda, S., Ariga, H., Nagasawa, S. (1995). Diversity of Sites for Measles Virus Binding and for Inactivation of Complement C3b and C4b on Membrane Cofactor Protein CD46. J. Biol. Chem. 270: 15148-15152 [Abstract] [Full Text]  
• Lin, H.-H., Stacey, M., Saxby, C., Knott, V., Chaudhry, Y., Evans, D., Gordon, S., McKnight, A. J., Handford, P., Lea, S. (2001). Molecular Analysis of the Epidermal Growth Factor-like Short Consensus Repeat Domain-mediated Protein-Protein Interactions. DISSECTION OF THE CD97-CD55 COMPLEX. J. Biol. Chem. 276: 24160-24169 [Abstract] [Full Text]